Wobble Genomics has just demonstrated that their circulating long RNA diagnostic platform has achieved a limit of detection which surpasses the current industry leader, Personalis, by more than an order of magnitude.

Wobble Genomics has developed a platform that detects circulating long RNA (clRNA), full-length RNA molecules recovered from a single blood draw, to profile how a patient's tumour is behaving at the resolution of drug-binding sites.